About: generic drugs

Health 12-03-2020

Commission’s new Pharmaceutical Strategy wants to touch core issues

The European Commission is planning to re-open basically all files related to the pharmaceutical industry with its roadmap for a new Pharmaceutical Strategy, seen by EURACTIV.com.
Health 29-01-2019

Pharma industry raises the alarm about stockpiling of generic drugs

The industry of innovative medicines is concerned with a recent vote in the European Parliament on the stockpiling of generic drugs, saying that it causes uncertainty over innovation in the pharmaceutical field.
Health 21-01-2019

Discussion heats up over stockpiling of generic drugs under patent protection

The Commission has announced its intention to add a manufacturing waiver to supplementary protection certificates (SPC), as part of its upgraded 2015 Single Market Strategy.
Health 23-10-2018

EU generics industry slams US ‘intervention’ in SPC manufacturing waiver talks

The EU generics industry has accused the US government of intervening in the ongoing discussion in the EU on the introduction of a Supplementary Protection Certificate (SPC) manufacturing waiver.
Health 10-10-2018

New drugs: how much are governments paying for innovation?

The European healthcare sector is divided over the “actual value” EU governments pay for the authorised and partly public-funded novel drugs, compared to medicines already on the market.
Health 12-06-2018

Andriukaitis: SPC manufacturing waiver does not damage pharma innovation

The European Commission’s proposal to add an SPC manufacturing waiver on exports will not damage innovation, as the pharma industry claims, and only intends to support small and medium generic drug companies, according to EU Health Commissioner Vytenis Andriukaitis.
Health 13-10-2017

New Commission study fuels generic drugs industry ‘manufacturing dispute’

The European Commission launched on Thursday (12 October) a public consultation on supplementary protection certificates for pharmaceutical products and the so-called Bolar patent research exemption.
Health 12-10-2017

Patients: ‘Think carefully’ before questioning orphan drugs’ incentives

Organisations of patients with rare diseases have warned EU policymakers to “think carefully” before reviewing the incentives in the orphan drugs regulation, claiming that the pharma industry should not be discouraged from investing in new therapies.
Health 10-10-2017

Andriukaitis: Supporting drug innovation is ‘the only way’

Backing innovation in the pharmaceutical market and developing new evidence-based economic models is the only way forward for future healthcare, according to EU Commissioner for Health and Food Safety Vytenis Andriukaitis.
Health 02-08-2017

EU drug agency announces ‘business continuity’ plan amid relocation uncertainty

The European Medicines Agency (EMA) presented on Tuesday (1 August) a business continuity plan aimed at tackling the potential challenges poised by its relocation from London to another member state after the Brexit decision.
Health 10-05-2017

Southern EU states present unified front in drug talks

Six southern member states have signed a common declaration, aiming to enhance their cooperation and jointly negotiate with the pharmaceutical industry on drug pricing.
Health 03-03-2017

EU Parliament demands clarity in public funding of drugs R+D

A European Parliament resolution adopted yesterday (2 March) called for transparency and clarity of public funding on research and development of new drugs, claiming that in such cases public investment should be reflected in the price of drugs.
Health 02-02-2017

Lawmakers warn EU pharma industry about drug pricing

Pressure is mounting on pharmaceutical companies to reconsider the way they do business by refocusing their efforts on meeting patient needs and health outcomes rather than their own profits.
Health 20-01-2017

OECD criticises ‘ineffective spending’ in healthcare

Health spending in countries that belong to the Organisation for Economic Cooperation and Development (OECD) is "at best ineffective and at worst wasteful", a new report has found.
Health 18-10-2016

Italy’s pharma scandal heats up drugs pricing debate

The European Consumer Organisation (BEUC) has urged the European Commission to investigate pharma-industry “unethical” practices on drug pricing, after a scandal revealed last week in Italy.
Hepatitis
Health 05-01-2016

Number of pharmaceutical drug approvals hits record high

2015 was a good year for innovation in medicine in both the EU and the US, according to data published on Monday (4 January).
CREDIT[Victor/Flickr]
Health 22-09-2014

France should give doctors bonuses to prescribe generic drugs

France is spending too much money on medicine and needs to promote the use of generic drugs. The French Court of Auditors recommends offering doctors incentives to prescribe cheaper generics to achieve this and capping their prescription budgets.
Health 01-07-2013

Regulators pave way for new wave of biosimilar drugs in Europe

European regulators have cleared the way for the first serious threat to the makers of multibillion-euro biotechnology drugs to treat diseases such as cancer and rheumatoid arthritis.
Trade & Society 04-06-2013

Pharma firms face EU fines for delaying cheaper drugs

European regulators will clamp down on "pay-for-delay" deals in the pharmaceutical sector this month, fining Denmark's Lundbeck and eight other generic drug manufacturers for limiting access of cheaper products to the market.
Public Affairs 14-01-2013

Drugmakers suffer decline in trust, report says

The overall corporate reputation of pharmaceutical companies declined in 2012 compared to 2011, according to an independent study by patients' organisations.
Global Europe 09-12-2010

EU-India summit to push for trade agreement by mid-2011

An EU-India summit tomorrow (10 December) will accelerate progress towards signing a Free Trade Agreement (FTA) by next spring, EU officials said. 
Trade & Society 06-12-2010

EU raids AstraZeneca and other drugmakers

EU antitrust regulators have raided the offices of some pharmaceutical companies, including AstraZeneca, suspected of colluding to block the market entry of cheaper generic drugs.
Health 12-06-2008

Industry blames weak EU patent system for generic drug delays

A number of hurdles related to the weakness of the European patent system prevent innovation and competition in the pharmaceutical sector and hinder timely market entry of cheap generic drugs, argues a generic medicine industry report.
Competition 17-01-2008

Big pharma groups raided in EU antitrust probe

The Commission has raided the offices of a number of top pharmaceutical companies to find out whether anti-competitive practices in the sector have hindered innovation and blocked the entry of cheap generics on the European market.
Contribute